Toprak Omer
Department of Nephrology, Ataturk Training and Research Hospital, Izmir, Turkey.
J Urol. 2007 Dec;178(6):2277-83. doi: 10.1016/j.juro.2007.08.054. Epub 2007 Oct 22.
Iodinated contrast medium is commonly used in diagnostic or interventional procedures in uroradiology. Procedures requiring the intravascular administration of iodinated contrast medium are becoming a great source of an iatrogenic disease known as contrast induced nephropathy. Identifying patients at high risk is the first step to minimize the overall risk of contrast induced nephropathy. This review describes conflicting and new risk factors for contrast induced nephropathy.
A MEDLINE/PubMed search from 1966 to 2006 was performed. All articles related to the use of contrast medium and the risk factors for contrast induced nephropathy were reviewed.
The classic risk factors for contrast induced nephropathy are preexisting renal failure, diabetes mellitus, advanced age, nephrotoxic agent administration, hypovolemia, use of a large amount of contrast medium or an ionic hyperosmolar contrast medium and congestive heart failure. Metabolic syndrome, prediabetes and hyperuricemia have been identified as new risk factors for contrast induced nephropathy. The use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, renal transplantation, diabetes mellitus with normal renal function, low osmolar contrast medium in patients at high risk for contrast induced nephropathy, multiple myeloma, female gender and cirrhosis have been classified as conflicting risk factors for contrast induced nephropathy.
Patients at risk for contrast induced nephropathy should be identified before urological procedures requiring contrast administration. In addition to the classic risk factors for contrast induced nephropathy, determining the metabolic syndrome, hyperuricemia and prediabetes as well as the use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers before performing procedures using contrast medium seems to be a useful guide to assess the risk of contrast induced nephropathy.
碘化造影剂常用于泌尿放射学的诊断或介入操作中。需要血管内注射碘化造影剂的操作正成为一种名为造影剂肾病的医源性疾病的重要来源。识别高危患者是将造影剂肾病的总体风险降至最低的第一步。本综述描述了造影剂肾病相互矛盾的风险因素和新的风险因素。
对1966年至2006年期间的MEDLINE/PubMed数据库进行了检索。对所有与造影剂使用及造影剂肾病风险因素相关的文章进行了综述。
造影剂肾病的经典风险因素包括既往存在的肾衰竭、糖尿病、高龄、使用肾毒性药物、血容量不足、使用大量造影剂或离子型高渗造影剂以及充血性心力衰竭。代谢综合征、糖尿病前期和高尿酸血症已被确定为造影剂肾病的新风险因素。使用血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂、肾移植、肾功能正常的糖尿病、高危造影剂肾病患者使用低渗造影剂、多发性骨髓瘤、女性和肝硬化已被归类为造影剂肾病的相互矛盾的风险因素。
在需要使用造影剂的泌尿外科操作前,应识别出有造影剂肾病风险的患者。除了造影剂肾病的经典风险因素外,在使用造影剂进行操作前,确定代谢综合征、高尿酸血症和糖尿病前期以及血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂的使用情况,似乎是评估造影剂肾病风险的有用指南。